Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Treasury Shares (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Treasury Shares for 9 consecutive years, with $256488.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 48.66% to $256488.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $256488.0, a 48.66% decrease, with the full-year FY2025 number at $256488.0, down 48.66% from a year prior.
  • Treasury Shares was $256488.0 for Q4 2025 at Madrigal Pharmaceuticals, down from $306982.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $757263.0 in Q2 2025 to a low of $199125.0 in Q1 2023.
  • A 3-year average of $408311.2 and a median of $343942.0 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: soared 166.5% in 2024, then plummeted 48.66% in 2025.
  • Madrigal Pharmaceuticals' Treasury Shares stood at $376117.0 in 2023, then surged by 32.82% to $499559.0 in 2024, then tumbled by 48.66% to $256488.0 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Treasury Shares are $256488.0 (Q4 2025), $306982.0 (Q3 2025), and $757263.0 (Q2 2025).